AR117404A2 - Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación - Google Patents

Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Info

Publication number
AR117404A2
AR117404A2 ARP190100714A ARP190100714A AR117404A2 AR 117404 A2 AR117404 A2 AR 117404A2 AR P190100714 A ARP190100714 A AR P190100714A AR P190100714 A ARP190100714 A AR P190100714A AR 117404 A2 AR117404 A2 AR 117404A2
Authority
AR
Argentina
Prior art keywords
dosage unit
constipation
treatment
unit including
prostaglandin
Prior art date
Application number
ARP190100714A
Other languages
English (en)
Inventor
Myra L Patchen
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23293447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR117404(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR117404A2 publication Critical patent/AR117404A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

Reivindicación 1: Una unidad de dosificación formulada como una cápsula blanda de gelatina, caracterizada porque comprende un relleno líquido comprendiendo un análogo de prostaglandina y un triglicérido de ácido graso de cadena mediana, donde el análogo de prostaglandina es 13,14-dihidro-15-ceto-16,16-difluoro prostaglandina E1 y el análogo de prostaglandina está presente en un rango de aproximadamente 6 - 96 mg.
ARP190100714A 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación AR117404A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33131601P 2001-11-14 2001-11-14

Publications (1)

Publication Number Publication Date
AR117404A2 true AR117404A2 (es) 2021-08-04

Family

ID=23293447

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ARP190100714A AR117404A2 (es) 2001-11-14 2019-03-21 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP020104349A AR037524A1 (es) 2001-11-14 2002-11-13 Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion
ARP140104956A AR098997A2 (es) 2001-11-14 2014-12-30 Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación

Country Status (15)

Country Link
US (3) US8097653B2 (es)
EP (2) EP1443938B1 (es)
JP (2) JP4852229B2 (es)
AR (3) AR037524A1 (es)
AT (1) ATE522218T1 (es)
BR (1) BR0214075A (es)
CA (1) CA2464420C (es)
CY (1) CY1115856T1 (es)
DK (2) DK1443938T3 (es)
ES (2) ES2524369T3 (es)
HK (1) HK1155649A1 (es)
LU (1) LU92826I2 (es)
PT (2) PT1443938E (es)
TW (1) TWI331920B (es)
WO (1) WO2003041716A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
ATE539756T1 (de) * 2002-10-23 2012-01-15 Sucampo Ag Prostaglandinsubstanzen für die behandlung von fettsucht
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物
US8337891B2 (en) * 2003-07-03 2012-12-25 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI387454B (zh) * 2004-09-02 2013-03-01 Sucampo Ag 治療胃腸道疾病之方法及組成物
MX2007010833A (es) * 2005-03-07 2009-02-17 Univ Chicago Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales.
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CA2602812C (en) * 2005-04-12 2014-11-18 Sucampo Ag Combined use of prostaglandin compound and proton pump inhibitor for the treatment of gastrointestinal disorders
EP1984027B1 (en) 2006-01-24 2015-12-30 R-Tech Ueno, Ltd. Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound
KR101393944B1 (ko) * 2006-01-24 2014-05-12 수캄포 아게 연질-젤라틴 캡슐 제형물
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
CN104958298A (zh) * 2009-09-18 2015-10-07 阿得罗公司 阿片样受体拮抗剂用于胃肠道疾病的用途
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5350141A (en) * 1976-10-18 1978-05-08 Ono Pharmaceut Co Ltd Stabilization of prostaglandin and prostaglandin analogues
GB1581886A (en) 1977-05-26 1980-12-31 May & Baker Ltd Prostanol derivatives
JPH0681728B2 (ja) 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
DE3873007T2 (de) * 1987-10-02 1992-12-03 Ueno Seiyaku Oyo Kenkyujo Kk Kathartica.
US5317032A (en) * 1987-10-02 1994-05-31 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Prostaglandin cathartic
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
CA2027814C (en) 1989-10-20 1996-07-30 Ryuji Ueno Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds
CA2030346C (en) 1989-11-22 2000-04-11 Ryuji Ueno Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
EP0455448B1 (en) * 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2046069C (en) 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
JP2938579B2 (ja) 1990-12-15 1999-08-23 株式会社上野製薬応用研究所 消化管壁保護剤
EP0503887B1 (en) * 1991-03-14 1996-08-28 R-Tech Ueno Ltd. Promotion of wound-healing with 15-keto-prostaglandin compounds
EP0554794B1 (en) * 1992-02-04 1998-07-29 Eisai Co., Ltd. Aminobenzoic acid derivatives
JP3183615B2 (ja) * 1994-06-03 2001-07-09 株式会社アールテック・ウエノ 肝・胆道系疾患処置剤
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
DK0857718T3 (da) * 1996-06-10 2002-12-16 Sucampo Ag Endothelinantagonist
DE19717005A1 (de) * 1997-04-23 1998-10-29 Kennametal Inc Spannfutter für Rundlaufwerkzeuge
PT978284E (pt) 1997-11-28 2008-10-07 Sucampo Ag Utilização de compostos 15-ceto-prostaglandina-e como antagonistas da endotelina
US6492417B1 (en) 1997-12-22 2002-12-10 Alcon Manufacturing, Ltd. 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists
AR026046A1 (es) * 1999-10-15 2002-12-26 R Tech Ueno Ltd NUEVA COMPOSICIoN Y MÉTODO PARA ESTABILIZAR LA MISMA
CA2404767C (en) 2000-04-06 2010-12-07 Sucampo Ag Bile secretion promoting composition containing a 15-keto prostaglandin
US6414016B1 (en) 2000-09-05 2002-07-02 Sucampo, A.G. Anti-constipation composition
TWI302100B (en) * 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
NZ529406A (en) 2001-05-18 2005-09-30 Sucampo Ag Halogenated prostaglandin derivatives for treating constipation and cleansing the gastrointestinal tract
MXPA04002006A (es) * 2001-08-31 2004-06-07 Sucampo Ag Analogos de prostagladina como abridor del canal de cloruro.
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
CN1753680B (zh) * 2002-12-27 2010-12-08 苏坎波公司 用于治疗腹部不适的前列腺素衍生物

Also Published As

Publication number Publication date
PT1443938E (pt) 2011-09-27
TWI331920B (en) 2010-10-21
JP2005513014A (ja) 2005-05-12
US8097653B2 (en) 2012-01-17
US8389542B2 (en) 2013-03-05
US20120088824A1 (en) 2012-04-12
EP1443938B1 (en) 2011-08-31
CY1115856T1 (el) 2017-01-25
DK2298314T3 (en) 2014-12-01
WO2003041716A1 (en) 2003-05-22
ES2368729T3 (es) 2011-11-21
AR037524A1 (es) 2004-11-17
ATE522218T1 (de) 2011-09-15
ES2524369T3 (es) 2014-12-05
JP4852229B2 (ja) 2012-01-11
CA2464420A1 (en) 2003-05-22
DK1443938T3 (da) 2011-09-26
AR098997A2 (es) 2016-06-22
PT2298314E (pt) 2014-12-03
CA2464420C (en) 2011-12-13
US20030119898A1 (en) 2003-06-26
EP1443938A1 (en) 2004-08-11
BR0214075A (pt) 2004-09-28
EP2298314A1 (en) 2011-03-23
LU92826I2 (fr) 2015-11-24
HK1155649A1 (en) 2012-05-25
JP2011201905A (ja) 2011-10-13
EP2298314B1 (en) 2014-09-03
US20130143958A1 (en) 2013-06-06
TW200300091A (en) 2003-05-16

Similar Documents

Publication Publication Date Title
AR117404A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
ES2174814T3 (es) Acidos grasos esenciales destinados en la prevencion de accidentes cardio-vasculares.
ES2195798T1 (es) Formulacion para mujeres menopausicas.
DE69707669D1 (de) Orale pharmazeutische zusammensetzungen mit sexualhormonen
ES2392590T3 (es) Formulación de cápsula de gelatina blanda
EE200200718A (et) Rasvhapete terapeutilised kombinatsioonid
AU2003238240A1 (en) ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
AR025599A1 (es) Metodo para mejorar la piel y el pelaje de mascotas
ES2136100T3 (es) Composicion lipida para productos cosmeticos que contienen trigliceridos de acidos grasos insaturados.
NZ600721A (en) Capsule formulation
GB0314624D0 (en) Inflammatory disease treatment
BRPI0009373B8 (pt) composições farmacêuticas orais contendo triglicerídeos de cadeia longa e tensoativos lipofílicos
CO5160323A1 (es) Formulaciones farmaceuticas mejoradas vir en combinacion con otros inhibidores de proteasa vih
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
PE20220506A1 (es) Composicion de recubrimiento comestible para recubrir productos frescos cosechados
RS52735B (en) APPLICATION OF A COMBINATION CONTAINING L-CARNITINE OR ALKANOIL L-CARNITINE, OIL-SOLUBLE OIL-BENZOQUINON AND OMEGA-3-POLYESATURATED FATTY ACID FOR PREPARATION OF NUTRITION OR MEDICINAL PRODUCTS
AU2441400A (en) Stabilized lipidic composition, method for the preparation thereof and nutritional product containing the same
ES2392221T3 (es) Composición farmacéutica que comprende una prostaglandina
CO4780020A1 (es) Formulaciones farmaceuticas de liberacion prolongada, que contienen mizolastina
AR042074A1 (es) Preparacion de sales de calcio de aceites poliinsaturados por saponificacion de aceites de animales marinos
AR039440A1 (es) Composiciones que comprenden acidos grasos de cadena corta y larga y metodos de utilizacion para el manejo del peso corporal
UA39351A (uk) Препарат для лікування і профілактики захворювань, що супроводжуються підвищеним зсіданням крові
AR035416A1 (es) Una composicion farmaceutica esteril y el metodo para prepararla
AR021830A1 (es) Utilizacion de acido docosahexaenoico y acido araquidonico para mejorar el crecimiento de bebes anteriores a termino
ECSP003646A (es) Metodo para mejorar la piel y el pelaje de mascotas

Legal Events

Date Code Title Description
FC Refusal